A Egli1, H Schmid2, E Kuenzli3, A F Widmer2, M Battegay2, H Plagge4, R Frei5, R Achermann6, M Weisser7. 1. Clinical Microbiology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland; Applied Microbiology Research, Department Biomedicine, University of Basel, Switzerland. 2. Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. 3. Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; Epidemiology, Biostatistics and Prevention Institute, University of Zürich, Zürich, Switzerland. 4. Hospital Pharmacy, University Hospital Basel, Basel, Switzerland. 5. Clinical Microbiology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland. 6. Applied Microbiology Research, Department Biomedicine, University of Basel, Switzerland. 7. Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; Department of Clinical Research, University Hospital Basel, Basel, Switzerland. Electronic address: maja.weisser@usb.ch.
Abstract
OBJECTIVE: In this study we aimed to analyse the association between use of daptomycin and MICs of daptomycin in Enterococcus faecium bacteraemia. METHODS: We prospectively enrolled patients aged ≥18 years with E. faecium bacteraemia hospitalized at the University Hospital Basel from 2008 to 2014. We determined daptomycin MICs by Etests and used pulsed field gel electrophoresis to determine clonal relatedness. We recorded the defined daily dosages of daptomycin (DDDs) per 100 patient-days and clinical data from charts. We correlated daptomycin MIC with use of daptomycin in patients with recurrence/persistence. RESULTS: In 195 E. faecium bacteraemias originating from 162 patients the median MIC for daptomycin was 2 mg/L (IQR 2-3); 30% (15.4%) isolates had a MIC ≥4 mg/L and 6 (3.1%) were resistant (MIC >4 mg/L) according to CLSI criteria. The usage of daptomycin increased more than four-fold from 0.36 DDDs/100 patient-days in 2008 to 1.6 in 2014. In 13 of 28 (42.9%) patients with a relapsing or persisting bacteraemia, the daptomycin MIC of the second isolate increased from a median of 2.0 to 2.5 mg/L (p 0.010); 3/13 (23.1%) developed resistance. All patients with the same clone in the first and second episode and an increase of daptomycin MIC had been treated with daptomycin (6/6 versus 1/7 p 0.005). CONCLUSIONS: Daptomycin MICs and Daptomycin usage increased over time. On an individual patient level daptomycin exposure was associated with an increased MIC in subsequent bacteraemia episodes. Diversity did not indicate a clonal origin and argues for a de novo development of resistance.
OBJECTIVE: In this study we aimed to analyse the association between use of daptomycin and MICs of daptomycin in Enterococcus faeciumbacteraemia. METHODS: We prospectively enrolled patients aged ≥18 years with E. faeciumbacteraemia hospitalized at the University Hospital Basel from 2008 to 2014. We determined daptomycin MICs by Etests and used pulsed field gel electrophoresis to determine clonal relatedness. We recorded the defined daily dosages of daptomycin (DDDs) per 100 patient-days and clinical data from charts. We correlated daptomycin MIC with use of daptomycin in patients with recurrence/persistence. RESULTS: In 195 E. faeciumbacteraemias originating from 162 patients the median MIC for daptomycin was 2 mg/L (IQR 2-3); 30% (15.4%) isolates had a MIC ≥4 mg/L and 6 (3.1%) were resistant (MIC >4 mg/L) according to CLSI criteria. The usage of daptomycin increased more than four-fold from 0.36 DDDs/100 patient-days in 2008 to 1.6 in 2014. In 13 of 28 (42.9%) patients with a relapsing or persisting bacteraemia, the daptomycin MIC of the second isolate increased from a median of 2.0 to 2.5 mg/L (p 0.010); 3/13 (23.1%) developed resistance. All patients with the same clone in the first and second episode and an increase of daptomycin MIC had been treated with daptomycin (6/6 versus 1/7 p 0.005). CONCLUSIONS:Daptomycin MICs and Daptomycin usage increased over time. On an individual patient level daptomycin exposure was associated with an increased MIC in subsequent bacteraemia episodes. Diversity did not indicate a clonal origin and argues for a de novo development of resistance.
Authors: Lindsay M Avery; Joseph L Kuti; Maja Weisser; Adrian Egli; Michael J Rybak; Evan J Zasowski; Cesar A Arias; German A Contreras; Pearlie P Chong; Samuel L Aitken; Adam J DiPippo; Jann-Tay Wang; Nicholas S Britt; David P Nicolau Journal: Clin Infect Dis Date: 2019-05-02 Impact factor: 9.079
Authors: Zulema Udaondo; Piroon Jenjaroenpun; Thidathip Wongsurawat; Erik Meyers; Courtney Anderson; James Lopez; Meera Mohan; Ruslana Tytarenko; Brian Walker; David Ussery; Atul Kothari; Se-Ran Jun Journal: Open Forum Infect Dis Date: 2020-05-23 Impact factor: 3.835
Authors: Clare L Kinnear; Elsa Hansen; Valerie J Morley; Kevin C Tracy; Meghan Forstchen; Andrew F Read; Robert J Woods Journal: PLoS Biol Date: 2020-12-17 Impact factor: 8.029
Authors: Rachael A Lee; Jason Goldman; Ghady Haidar; Jessica Lewis; Sana Arif; Jonathan Hand; Ricardo M La Hoz; Stephanie Pouch; Eric Holaday; Heather Clauss; Keith S Kaye; Anoma Nellore Journal: Open Forum Infect Dis Date: 2022-01-22 Impact factor: 3.835
Authors: Mathilde Boumasmoud; Vanina Dengler Haunreiter; Tiziano A Schweizer; Lilly Meyer; Bhavya Chakrakodi; Peter W Schreiber; Kati Seidl; Denise Kühnert; Roger D Kouyos; Annelies S Zinkernagel Journal: mBio Date: 2022-03-28 Impact factor: 7.786